{"id":75472,"date":"2026-06-01T07:46:29","date_gmt":"2026-06-01T07:46:29","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/75472\/"},"modified":"2026-06-01T07:46:29","modified_gmt":"2026-06-01T07:46:29","slug":"switzerland-cordenpharma-expands-global-peptides-platform-in-us-and-china","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/75472\/","title":{"rendered":"Switzerland: CordenPharma expands global peptides platform in US and China"},"content":{"rendered":"<p>Switzerland-based global CDMO, CordenPharma, has agreed to acquire\u00a0<a href=\"https:\/\/www.ambiopharm.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">AmbioPharm<\/a>, a US-headquartered peptide API CDMO, from Carlyle.<\/p>\n<p>The acquisition builds on CordenPharma\u2019s global facility network of 11 sites in Europe and North America. AmbioPharm employs approximately 400 people across its two sites in South Carolina and Shanghai, which add differentiated peptide manufacturing capabilities to CordenPharma\u2019s existing peptides platform and expertise.<\/p>\n<p>\u201cAs peptide programmes become more complex and advanced, customers value CDMO partners who can offer both upstream scientific route selection and process robustness with downstream manufacturing scale and built-in geographic flexibility,\u201d said Dr <a href=\"https:\/\/www.linkedin.com\/in\/michael-quirmbach-ba63a73\/\" rel=\"nofollow noopener\" target=\"_blank\">Michael Quirmbach<\/a>, president and CEO of CordenPharma. \u201cAmbioPharm\u2019s capabilities perfectly complement our existing peptide expertise.\u201d<\/p>\n<p><a href=\"https:\/\/www.investorsinhealthcare.com\/articles\/germany-astorg-acquires-cordenpharma-from-icig\/\" rel=\"nofollow noopener\" target=\"_blank\">Astorg acquired CordenPharma<\/a> from \u00a0International Chemical Investors Group (ICIG) in 2022, since when the company has continued to expand its global peptides platform through strategic investments and expanded manufacturing capacity.<\/p>\n<p>\u201cThis acquisition . . . enhances the company\u2019s strategic positioning and supports significant long-term growth opportunities in peptides,\u201d said\u00a0Astorg director <a href=\"https:\/\/www.linkedin.com\/in\/antoine-thomas-b599393a\/?locale=en\" rel=\"nofollow noopener\" target=\"_blank\">Antoine Thomas<\/a>.\u00a0<\/p>\n<p>As part of the transaction, AmbioPharm\u2019s shareholders will reinvest into the combined business.<\/p>\n<p>Carlyle acquired AmbioPharm in 2018.<\/p>\n<p>\u201cSince our investment in AmbioPharm, we have worked closely with the company as a strategic shareholder to enhance its operations and expand its global footprint,\u201d said <a href=\"https:\/\/www.linkedin.com\/in\/ling-yang-0269a929\/\" rel=\"nofollow noopener\" target=\"_blank\">Ling Yang<\/a>, partner and head of Healthcare at Carlyle Asia. \u201cWe remain confident in the strong growth potential of the global peptide CDMO market and look forward to continuing to support the combined business.\u201d<\/p>\n<p>BNP Paribas\u00a0acted as exclusive financial advisor to AmbioPharm.<\/p>\n<p>Press release: <a href=\"https:\/\/cordenpharma.com\/articles\/press-release-cordenpharma-acquires-ambiopharm-to-expand-global-peptide-api-capacity\/\" rel=\"nofollow noopener\" target=\"_blank\">CordenPharma Acquires Peptide CDMO AmbioPharm | CordenPharma<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Switzerland-based global CDMO, CordenPharma, has agreed to acquire\u00a0AmbioPharm, a US-headquartered peptide API CDMO, from Carlyle. The acquisition builds&hellip;\n","protected":false},"author":2,"featured_media":75473,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[39604,39605,39606,26863,16407,39607,39608,39609,17],"class_list":["post-75472","post","type-post","status-publish","format-standard","has-post-thumbnail","category-switzerland","tag-ambiopharm","tag-antoine-thomas","tag-astorg","tag-bnp-paribas","tag-carlyle","tag-cordenpharma","tag-ling-yang","tag-michael-quirmbach","tag-switzerland"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116673746383549752","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/75472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=75472"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/75472\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/75473"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=75472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=75472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=75472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}